MOTS-c in women: what the research actually shows

Last updated 2026-07-25

Is there any human research on MOTS-c in women specifically?

No. As of this writing, there's no published clinical trial testing MOTS-c in women, or comparing outcomes by sex in humans at all. The 2023 Frontiers in Endocrinology review that surveys MOTS-c's path toward "therapeutic exploitation" describes a peptide still largely in preclinical territory, not one with sex-specific human data to report ^[1]. That matters more than it sounds like it should. A lot of the online chatter about MOTS-c for women (fat loss, menopause metabolism, fertility) is extrapolated from rodent studies, sometimes rodent studies that didn't even test both sexes. If you're a researcher trying to evaluate this compound seriously, the honest starting point is: we don't have the human data yet, full stop. The closest thing to female-specific evidence is a 2022 study in Pharmacological Research on gestational diabetes, which we cover in detail below. It's real data, but it's a rat model, not a human trial ^[2]. Keep that distinction in mind every time you see MOTS-c and "women" in the same sentence online.

What does the gestational diabetes study actually show?

A 2022 paper in Pharmacological Research found that MOTS-c "relieves hyperglycemia and insulin resistance in gestational diabetes mellitus" in an animal model ^[2]. This is the single most directly female-relevant MOTS-c study in the current literature, because gestational diabetes is a pregnancy-specific condition. The study is preclinical. It doesn't establish a dose, a safety profile, or an effect size in pregnant women, and pregnancy is exactly the context where you'd want the most caution before extrapolating from rodents. Nobody should read this paper as a reason to try MOTS-c during pregnancy. What it does establish is a plausible mechanistic link between MOTS-c and glucose regulation in a pregnancy-related insulin resistance model, which is worth knowing about if you're tracking where the field might go next, not where it currently is. For context, the foundational 2015 Cell Metabolism paper that put MOTS-c on the map showed the peptide "promotes metabolic homeostasis and reduces obesity and insulin resistance" in mice ^[3]. That work established the metabolic mechanism broadly; the gestational diabetes paper applied a version of that mechanism to a pregnancy-specific model seven years later.

Does MOTS-c help with ovarian cancer?

There's one notable cancer study, and it points toward suppression, not promotion, of tumor growth. A 2024 paper in Advanced Science found that MOTS-c "suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination," describing a specific molecular mechanism by which the peptide interferes with cancer cell processes ^[4]. This is cell and mouse work, not a human trial, and one study on one cancer type doesn't tell you anything about MOTS-c's relationship to breast cancer, endometrial cancer, or any other female-prevalent cancer. It's a genuinely interesting finding (a mitochondrial peptide with a specific anti-cancer mechanism in ovarian tissue) but it's early. If you see this study cited as evidence that MOTS-c "prevents cancer" or is broadly protective for women, that's an overreach the paper itself doesn't make. Worth noting: MOTS-c's nuclear translocation under metabolic stress, described in the 2018 Cell Metabolism paper that first showed the peptide moves into the nucleus to regulate gene expression in response to stress ^[5], is likely the broader mechanistic thread connecting these disease-specific findings. The ovarian cancer study and the antiviral and anti-fibrotic studies described elsewhere in the literature all seem to trace back to MOTS-c's ability to reach into the nucleus and change what genes get turned on.

Does MOTS-c affect estrogen, hormones, or menopause?

There's no published research directly testing MOTS-c against estrogen levels, menopausal symptoms, or hormone replacement interactions. This is a real gap, not an area where the answer is simply "no effect." Nobody has run that study yet, and the peptide's core studied mechanisms (AMPK activation, mitochondrial stress signaling, nuclear gene regulation ^[5]) are the kind of pathways that could plausibly intersect with metabolic changes during menopause, given that menopause itself is associated with shifts in insulin sensitivity and fat distribution. But plausible mechanism is not evidence. If a supplement seller tells you MOTS-c is specifically formulated or studied for menopausal metabolism, that claim isn't backed by any citation currently in the literature. The honest answer is: the biology is interesting enough that someone should study this, and as of now, nobody has published it.

Is the 'exercise in a pill' claim true for women specifically?

The "exercise mimetic" framing is a marketing simplification of a real but narrower finding: MOTS-c is a mitochondrial-derived peptide whose circulating levels and downstream signaling change with exercise, a relationship reviewed in a 2021 paper in Biochimica et Biophysica Acta on mitochondrial-derived peptides and exercise ^[6] and again in a 2022 Diabetes & Metabolism Journal review on exercise, mitohormesis, and MOTS-c ^[7]. What those papers show is correlation and mechanism: MOTS-c participates in some of the same AMPK-driven signaling that exercise triggers. What they don't show is that injecting MOTS-c reproduces the full physiological benefit of an exercise session, in women or anyone else. No study has compared MOTS-c injection against a bout of actual exercise for the range of things exercise does (cardiovascular conditioning, bone loading, mood, sleep architecture). Calling it "exercise in a pill" (or a pen) skips past that entire body of missing comparison data. A separate 2025 paper in Scientific Reports found MOTS-c "mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3" in what looks like a rodent liver fibrosis model ^[8]. That's a legitimate use of the word "mimics" in a specific tissue-and-pathway context. It is not license to generalize that MOTS-c mimics exercise everywhere in the body, for either sex.

What does MOTS-c do for muscle and bone that would matter to women?

This is where the animal data gets more detailed, and where sex-specific concerns (sarcopenia risk after menopause, osteoporosis risk after menopause) intersect with an evidence base that mostly hasn't been broken out by sex. On muscle: a 2021 paper in the American Journal of Physiology - Endocrinology and Metabolism found MOTS-c "reduces myostatin and muscle atrophy signaling" ^[9], and a 2024 paper in the same journal found the peptide "attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration" ^[10]. A 2022 paper in Peptides found MOTS-c "promotes muscle differentiation in vitro" ^[11], and a 2024 iScience paper found it "modulates skeletal muscle function by directly binding and activating CK2" ^[12]. That's a consistent thread across four separate papers pointing at a real muscle-preservation mechanism. On bone: a 2023 review in Frontiers in Physiology covers MOTS-c's role in bone metabolism regulation ^[13]. Postmenopausal bone loss is one of the biggest sex-specific health issues in aging, so a peptide with a documented bone metabolism mechanism is worth tracking. But "worth tracking" is different from "proven to prevent osteoporosis." These are mechanistic and animal studies. Nobody has run a trial testing MOTS-c against bone density outcomes in postmenopausal women. A 2025 paper in Free Radical Biology & Medicine also found MOTS-c "attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism" ^[14], which is relevant to joint health broadly but again not sex-specific data. If you're specifically interested in the injection mechanics for muscle-related use, our guide to MOTS-c injection sites covers the practical side of that question. And if you're weighing storage logistics before you even get to the injection question, does MOTS-c need to be refrigerated covers that separately.

What about fat loss and metabolic health in women?

The metabolic foundation here is the 2015 Cell Metabolism paper, which found that MOTS-c "promotes metabolic homeostasis and reduces obesity and insulin resistance" in a mouse model ^[3], and a 2023 paper in Metabolites titled "MOTS-c Functionally Prevents Metabolic Disorders" that extends similar findings ^[15]. Neither study broke results out by sex in a way that's been widely reported, and neither is a human trial. A 2023 review in Diabetes & Metabolism Journal covers MOTS-c's relationship to diabetes and aging-related disease broadly ^[16], and a 2025 paper in Experimental & Molecular Medicine found the peptide "prevents pancreatic islet cell senescence to delay diabetes" in what appears to be an animal model ^[17]. Again: real mechanistic threads, zero human trial data specific to women, and no data at all on how MOTS-c performs against, say, GLP-1 drugs or lifestyle intervention in a head-to-head. If a seller claims MOTS-c is "proven" for female fat loss, ask them for the human trial. There isn't one yet.

Are there safety concerns specific to women?

There's no published safety data broken out by sex for MOTS-c in humans, because there's essentially no published human safety data for MOTS-c at all outside of general peptide-therapy reviews. A 2026 paper in Sports Medicine reviewing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is the kind of source that would flag sex-specific safety signals if any existed in the literature it reviewed ^[18], and it treats MOTS-c within the broader unapproved-peptide category, not as a peptide with an established human safety profile. The bigger practical issue for women considering MOTS-c is the same issue that applies to everyone: MOTS-c is not FDA-approved for any indication. You can check the FDA's own approved drug database directly, and MOTS-c won't appear in it ^[19]. It's also not on either FDA bulk drug substances list that would make it eligible for compounding under section 503A or 503B ^[20][21]. That means any product being sold as "MOTS-c" is operating outside the regulatory framework that would normally require documented purity, sterility, and dosing data, and pregnancy or breastfeeding status is exactly the kind of variable that unregulated sourcing has no mechanism to account for. If you're pregnant, trying to conceive, or breastfeeding, the responsible position given current evidence is: there's no human safety data to reassure you, and the one relevant animal study (gestational diabetes) is not the same thing as a human safety trial ^[2]. That's not fear-mongering, it's just an accurate description of the evidence gap. For readers who've gotten past the research question and are now evaluating actual products, how to verify MOTS-c quality covers the sourcing side.

Does MOTS-c interact with hormonal birth control or HRT?

No study has tested this. There's no published research on interactions between MOTS-c and oral contraceptives, IUDs, or hormone replacement therapy of any kind. This is simply unstudied territory, and anyone claiming otherwise is speculating past the available evidence. The mechanistic overlap worth flagging: MOTS-c's documented effects run through AMPK and mitochondrial stress pathways ^[5], and hormonal contraceptives and HRT can also shift metabolic markers like insulin sensitivity and lipid profiles. Whether those two things interact in a meaningful way is an open question, not a known risk or a known non-issue. If you're on hormonal medication and considering MOTS-c, that's a conversation for a physician who knows your full history, not something a peptide vendor's FAQ page can answer for you.

What research gaps matter most for women considering MOTS-c?

Three gaps stand out. First, there is no human clinical trial of MOTS-c in any population, so "in women" specifically is a subset of a data set that doesn't yet exist. Second, the studies that do exist and touch female-relevant biology (gestational diabetes ^[2], ovarian cancer ^[4]) are single papers, not replicated bodies of work, and both are animal or cell models. Third, none of the muscle, bone, or metabolic mechanism studies that would matter most for postmenopausal women have been run with sex as a study variable. A 2019 BioEssays review frames MOTS-c as "a mitochondrial-encoded regulator of the nucleus" ^[22], which is a genuinely interesting way to think about a peptide that seems to act as a stress-response signal shuttling information from mitochondria to the genome. That framing is legitimate biology. It's also a long way from a therapeutic claim you can act on, in women or in anyone else, right now. For readers evaluating sourcing quality once a product decision is actually on the table, see how to verify MOTS-c quality. And if dosing mechanics are the next question on your list, MOTS-c injection sites covers that ground too.

So what's the bottom line for a researcher evaluating MOTS-c for women?

Treat MOTS-c as a peptide with interesting, fast-growing preclinical biology and almost no human trial data, and treat the "in women" question as a subset of that same gap. The gestational diabetes study ^[2] and the ovarian cancer study ^[4] are the two papers that actually touch female-specific biology; everything else is general mechanism work in male or unspecified-sex rodents and cell lines. We cover the practical side of MOTS-c handling and use elsewhere on this site: if you're weighing whether cold storage matters, see does MOTS-c need to be refrigerated. For dosing logistics once you're past the research question, MOTS-c injection sites covers the practical mechanics. MOTS-c Co doesn't compound or manufacture anything itself; for readers who've already decided to source a product, the responsible path is a provider-reviewed route through a pharmacy partner that documents testing and sourcing, not an anonymous online seller with no traceability, and how to verify MOTS-c quality walks through what that verification actually looks like. The honest summary: the biology is worth watching. The evidence base for using MOTS-c specifically because you're a woman, for any indication, isn't there yet.

Frequently asked questions

Has MOTS-c been tested in a human clinical trial for women?

No. There is currently no published human clinical trial of MOTS-c in women or in any population. The available evidence is entirely preclinical: rodent models and cell culture studies, including a rat gestational diabetes study and a cell/mouse ovarian cancer study, neither of which are human trials.

Can MOTS-c help with gestational diabetes?

A 2022 study in Pharmacological Research found MOTS-c "relieves hyperglycemia and insulin resistance in gestational diabetes mellitus" in an animal model ^[1]. That's a real preclinical finding, not a human trial result, and pregnancy is exactly the situation where extrapolating from rodents to people carries the most risk.

Does MOTS-c cause or prevent ovarian cancer?

The one relevant study found the opposite of causing cancer: a 2024 paper in Advanced Science showed MOTS-c "suppresses ovarian cancer progression" through a specific molecular mechanism in cell and mouse models ^[2]. This is early, mechanism-focused work, not evidence MOTS-c prevents cancer in humans.

Is MOTS-c safe during pregnancy or breastfeeding?

There's no human safety data for MOTS-c in pregnancy or breastfeeding. The one directly relevant study is an animal model of gestational diabetes ^[1], not a human safety trial. MOTS-c also isn't FDA-approved or on the FDA's bulk compounding substance lists ^[20][21], so no regulated safety profile exists for this use.

Does MOTS-c affect menopause or estrogen levels?

No published study has tested MOTS-c against menopausal symptoms, estrogen levels, or hormone therapy interactions. The peptide's studied mechanisms (AMPK activation, mitochondrial stress signaling) plausibly intersect with menopausal metabolic changes, but plausibility isn't evidence. This is an open research question, not an answered one.

Is MOTS-c really 'exercise in a pill' for women?

That framing overstates the evidence. Reviews on MOTS-c and exercise show the peptide participates in some of the same signaling pathways exercise triggers ^[6][7], and one study found it "mimics exercise" in a specific liver fibrosis pathway ^[8]. No study shows MOTS-c reproduces the full range of exercise benefits in women or anyone else.

Can MOTS-c help preserve muscle mass after menopause?

Animal studies show MOTS-c reduces myostatin signaling ^[9], attenuates immobilization-induced muscle atrophy ^[10], and promotes muscle differentiation in vitro ^[11]. These are real mechanistic findings relevant to age-related muscle loss, but none were tested in postmenopausal women or broken out by sex, so no human conclusion can be drawn yet.

Does MOTS-c help with bone density or osteoporosis risk?

A 2023 review in Frontiers in Physiology covers MOTS-c's role in bone metabolism regulation ^[13], which is mechanistically relevant to postmenopausal osteoporosis risk. No study has tested MOTS-c against bone density outcomes in women, so this remains a research direction, not a demonstrated benefit.

Does MOTS-c interact with birth control pills or HRT?

No study has examined this. MOTS-c's documented pathways overlap mechanistically with metabolic effects of hormonal medications, but no research has tested actual interaction. Anyone on hormonal contraception or HRT considering MOTS-c should discuss it with a physician who knows their full medical history, not rely on vendor claims.

Is MOTS-c FDA-approved for use in women?

No. MOTS-c is not FDA-approved for any indication, in women or otherwise; it does not appear in the FDA's Drugs@FDA database of approved products ^[19]. It also isn't on the FDA's 503A or 503B bulk drug substance lists that govern legal compounding ^[20][21].

Where does the female-specific MOTS-c research actually come from?

The two most directly female-relevant papers are a 2022 rat gestational diabetes study in Pharmacological Research ^[1] and a 2024 cell/mouse ovarian cancer study in Advanced Science ^[2]. Nearly all other MOTS-c research (metabolism, muscle, bone) doesn't report results by sex.

Should women take MOTS-c for weight loss?

There's no human trial data on MOTS-c and weight loss in women or anyone else. The foundational evidence is a 2015 mouse study showing reduced obesity and insulin resistance ^[4]. That's a legitimate mechanistic finding, not proof the peptide works for weight loss in people.

Sources

1. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus animal model
2. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in cell/mouse models
3. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide still being explored for therapeutic use
4. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in a mouse model
5. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
6. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides including MOTS-c in the context of exercise
7. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review of exercise, mitohormesis, and MOTS-c signaling
8. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise to combat diabetic liver fibrosis via the Keap1-Nrf2-Smad2/3 pathway
9. PubMed, American Journal of Physiology - Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
10. PubMed, American Journal of Physiology - Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
11. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
12. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
13. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in bone metabolism regulation
14. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
15. PubMed, Metabolites 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in preclinical models
16. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review of MOTS-c's relationship to diabetes and aging-related disease
17. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in an animal model
18. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies including MOTS-c for musculoskeletal and athletic use
19. FDA, Drugs@FDA approved drug products database: MOTS-c does not appear in the FDA's database of approved drug products
20. eCFR, 21 CFR 216.23 (503A Bulks List): MOTS-c is not on the FDA's 503A bulk drug substances list governing legal compounding
21. eCFR, 21 CFR 216.24 (503B Bulks List): MOTS-c is not on the FDA's 503B bulk drug substances list governing outsourcing facility compounding
22. PubMed, BioEssays 2019 (PMID 31378979): MOTS-c is characterized as a mitochondrial-encoded regulator of the nucleus